omega-3 ethylester concentrate / Generic mfg. - LARVOL DELTA

Splenic Vein Thrombosis Complicating Hypertriglyceridemia-Induced Acute Pancreatitis in Diabetic Ketoacidosis: A Rare Clinical Tetrad. (PubMed, Cureus) - "Therapeutic intravenous heparin was initiated, followed by transition to oral apixaban. He was discharged in stable condition on basal-bolus insulin, atorvastatin, fenofibrate, and omega-3 acid ethyl esters with multidisciplinary follow-up. This case describes a rare clinical tetrad linking DKA, severe HTG, HTG-AP, and SVT. It highlights the importance of early recognition and prompt multidisciplinary management of both the metabolic and thrombotic complications associated with this uncommon presentation."

Journal • Cardiovascular • Diabetes • Dyslipidemia • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hypertension • Hypertriglyceridemia • Inflammation • Metabolic Disorders • Pain • Pancreatitis • Portal Hypertension • Severe Hypertriglyceridemia • Thrombosis • Type 2 Diabetes Mellitus

LungVITamin D and OmegA-3 Trial (lungVITAL) (clinicaltrials.gov) - P=N/A | N=25871 | Active, not recruiting | Sponsor: Brigham and Women's Hospital | Trial completion date: Feb 2025 ➔ Nov 2027

Trial completion date • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Infectious Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases

Drugs for hypertriglyceridemia. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Dyslipidemia • Hypertriglyceridemia

Development of Eudragit L100/sodium alginate-carrageenan core/shell nanofiber patches for dermal delivery of omega-3 acid ethyl ester. (PubMed, Int J Pharm) - "Oxidized DHA/EPA-loaded mats exhibited concentration-dependent suppression of bacterial growth, with a stronger effect against the Gram-positive Staphylococcus aureus than against the Gram-negative Escherichia coli, whereas non-oxidized mats showed weaker activity. Overall, EL100/SA-CRG core-shell nanofibers provide a dry, handleable, and biologically tolerated platform for sustained topical delivery of labile omega-3 ethyl esters, thereby supporting their further development as advanced dermal patches for skin repair and dermocosmetic applications."

Journal • Infectious Disease

Severe Hypertriglyceridemia Managed in a Pregnant Patient Using Nonstatin Therapies. (PubMed, JACC Case Rep) - "Severe HTG in pregnancy is associated with increased risk of maternal-fetal morbidity. Management of severe HTG in pregnancy includes preconception risk assessment, multidisciplinary care, intensive lifestyle modification, selective use of nonstatin agents, and monitoring throughout and after pregnancy."

Journal • Critical care • Diabetes • Dyslipidemia • Hypertriglyceridemia • Metabolic Disorders • Obstetrics • Severe Hypertriglyceridemia • Type 2 Diabetes Mellitus

The Effect of Omega 3 Supplementation on Postoperative Delirium in Elderly Patients Undergoing Major Cardiac Surgery (clinicaltrials.gov) - P2 | N=1 | Terminated | Sponsor: University of Missouri-Columbia | N=90 ➔ 1 | Trial completion date: Feb 2027 ➔ Apr 2026 | Enrolling by invitation ➔ Terminated | Trial primary completion date: Aug 2026 ➔ Apr 2026; Unable to find a sufficient number of suitable study patients.

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Cardiovascular • CNS Disorders • Geriatric Disorders

Platelet Plummet: First Case of Icosapent Ethyl-induced Thrombocytopenia (AACE 2026) - "His triglyceride levels peaked at 2,948 mg/dL but improved to 300 mg/dL with initiation of gemfibrozil and ω-3-acid ethyl esters (Lovaza). Increased risk of bleeding, particularly in patients receiving concomitant antithrombotic therapy, is a possible side effect of using eicosapentaenoic acids such as Vascepa. Rivaroxaban has been documented to cause isolated thrombocytopenia only a handful of times through a mechanism that is not well"

Clinical • Cardiovascular • Diabetes • Dyslipidemia • Endocrine Disorders • Hematological Disorders • Hypertriglyceridemia • Metabolic Disorders • Thrombocytopenia • Thrombosis • Type 2 Diabetes Mellitus

Marine-derived Bioactives as Novel Interventions for Cardiovascular Disorders. (PubMed, Cardiovasc Hematol Disord Drug Targets) - "Marine-derived bioactive compounds represent a rich, underexplored resource for novel interventions against cardiovascular disorders. Rigorous clinical validation and sustainable harvesting strategies are essential to fully realize their therapeutic potential."

Journal • Atherosclerosis • Cardiovascular

VITAL: Study of Vitamin D and Omega-3 Supplementation for Preventing Diabetes (clinicaltrials.gov) - P3 | N=22220 | Completed | Sponsor: Brigham and Women's Hospital | Active, not recruiting ➔ Completed | Phase classification: PN/A ➔ P3

Phase classification • Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Refractory Severe Hypertriglyceridemia With Insulin Resistance Treated by Early Plasmapheresis (SCCM 2026) - "Fenofibrate and omega‑3 ethyl esters were started, and insulin was titrated...The American Society for Apheresis assigns plasmapheresis a Category II recommendation for HTG-induced pancreatitis. Our experience underscores the importance of aligning these "moving parts" promptly, especially in resource-limited settings or off hours."

Cardiovascular • Diabetes • Dyslipidemia • Gestational Diabetes • Hypertension • Hypertriglyceridemia • Metabolic Disorders • Pancreatitis • Severe Hypertriglyceridemia • LPL

Effects of Fish Oil and Red Wine on Oxidative Stress Biomarkers (clinicaltrials.gov) - P=N/A | N=40 | Active, not recruiting | Sponsor: Carsten Skarke, MD | Trial primary completion date: Nov 2027 ➔ Nov 2028

Biomarker • Trial primary completion date

Crossover Trial of Pemafibrate and Omega-3-Acid Ethyl Esters for Hypertriglyceridemia in Patients with Cardiovascular Disease. (PubMed, JMA J) - "Pemafibrate may be an effective first choice for hypertriglyceridemia, and add-on DHA+EPA may be beneficial when pemafibrate is not sufficiently effective. Findings need to be confirmed in larger studies."

Journal • Cardiovascular • Dyslipidemia • Fibrosis • Hypertriglyceridemia • Immunology • Metabolic Disorders

Omega-3CIPNII/A two-arm, open-label, multicenter phase II study on the efficacy and safety of omega-3 polyunsaturated fatty acids combined with levocarnitine in preventing chemotherapy-induced peripheral neuropathy in colorectal cancer patients receiving postoperative adjuvant chemotherapy regimens containing oxaliplatin (ChiCTR) - P2 | N=106 | Recruiting | Sponsor: Jiangsu Hengrui Medicine Co., Ltd.; The First Affiliated Hospital of Nanchang University

New P2 trial • Colorectal Cancer • Oncology • Pain • Solid Tumor

Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction (clinicaltrials.gov) - P2 | N=66 | Recruiting | Sponsor: National Cancer Institute (NCI) | Trial primary completion date: Oct 2027 ➔ Jan 2027

Trial primary completion date • Breast Cancer • Obesity • Oncology • Solid Tumor

Effects of Fish Oil and Red Wine on Oxidative Stress Biomarkers (clinicaltrials.gov) - P=N/A | N=40 | Active, not recruiting | Sponsor: Carsten Skarke, MD | Trial completion date: Nov 2028 ➔ Nov 2029 | Trial primary completion date: Nov 2026 ➔ Nov 2027

Biomarker • Trial completion date • Trial primary completion date

Severe Hypertriglyceridemia in Pregnancy: A Case Highlighting Therapeutic Challenges (AHA 2025) - "Prior to conception, she had been treated with a biguanide for diabetes and a combination of fish oil, fenofibrate, and a statin for HTG, which were discontinued for fetal safety. Given the markedly elevated TG level, a multidisciplinary decision was made to urgently reinitiate lipid-lowering therapy with omega-3 acid ethyl esters 4g daily (Lovaza) and subcutaneous insulin glargine...Traditional lipid-lowering agents, including statins, PCSK9 inhibitors, ezetimibe, bempedoic acid, and lomitapide, are generally avoided during pregnancy due to limited fetal safety data...Thus, cardio-obstetric management of high-risk women with metabolic disorders should center around preconception risk assessment, multidisciplinary care, intensive lifestyle modification, selective use of non-statin agents or apheresis, and vigilant monitoring throughout pregnancy. There remains a significant gap in evidence regarding the safety and efficacy of lipid-lowering therapies during pregnancy,..."

Clinical • Diabetes • Dyslipidemia • Gynecology • Hypertriglyceridemia • Obstetrics • Pancreatitis • Severe Hypertriglyceridemia • Type 2 Diabetes Mellitus

Management of Acute Pancreatitis Due to Hypertriglyceridemia in Pregnancy (ACG 2025) - "Plasmapheresis was considered due to the severity and risk to the pregnancy, but ultimately, the patient was treated supportively and improved clinically with bowel rest, insulin drip, fenofibrate, Niaspan, and Lovaza. In conclusion, patients with suspected familial hypertriglyceridemia should be counseled on triglyceride management before pregnancy to prevent this complication. Furthermore, in the event of developing hypertriglyceridemia-induced acute pancreatitis in pregnancy, plasmapheresis can be considered for treatment."

Diabetes • Dyslipidemia • Gastroenterology • Hepatology • Hypertriglyceridemia • Metabolic Disorders • Pancreatitis • Type 2 Diabetes Mellitus

Effect of Omega-3 Free Fatty Acid Supplementation on Crohn's Disease: A Meta-Analysis of Randomized Controlled Trials (ACG 2025) - "used 12-month fish oil capsules; Lorenz-Meyer et al., an 8-week EPA-enriched enteral formula; Feagan et al., Omacor for 58 weeks... Five randomized controlled trials (n = 414) were included. The pooled mean difference in CDAI scores between omega-3 and control groups was 38.73 (95% CI: -10.85 to 88.32, p = 0.126), showing no statistically significant effect. Heterogeneity was high (I² = 97.5%, τ² = 2674.12, Q = 79.18, p < 0.0001)."

Retrospective data • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease

Trends in utilization and cost of triglyceride-lowering therapies among Medicare beneficiaries: An analysis from the Medicare part D database. (PubMed, Am J Prev Cardiol) - "We used the Medicare Part D Prescriber dataset from 2013 to 2021 to identify all generic and brand name formulations of triglyceride-lowering therapies (fibrates, omega-3 acid ethyl esters, and niacin)...These trends likely reflect changes in the evidence base and guideline recommendations for hypertriglyceridemia treatment. While most beneficiaries received generic medications when available, substantial spending on brand name medications persists, indicating potential missed opportunities for cost savings."

Journal • Medicare • Reimbursement • US reimbursement • Atherosclerosis • Cardiovascular • Dyslipidemia • Hypertriglyceridemia

The Effect of Omega 3 Supplementation on Postoperative Delirium in Elderly Patients Undergoing Major Cardiac Surgery (clinicaltrials.gov) - P2 | N=90 | Enrolling by invitation | Sponsor: University of Missouri-Columbia | Not yet recruiting ➔ Enrolling by invitation

Enrollment open • Cardiovascular • CNS Disorders • Geriatric Disorders

Phase II Trial to Modulate Intermediate Endpoint Biomarkers in Former and Current Smokers (clinicaltrials.gov) - P2 | N=19 | Active, not recruiting | Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Trial primary completion date: Jun 2025 ➔ Mar 2025

Biomarker • Trial primary completion date • Lung Cancer • Oncology • Pulmonary Disease • Respiratory Diseases • Solid Tumor

OMECARDIO trial: a randomized, double-blind, placebo-controlled study on the impact of omega-3 on inflammageing biomarkers and vascular stiffness in hypertensive and dyslipidemic patients (ESC-WCC 2025) - "Participants were randomly assigned (1:1) to receive either 2 grams of omega-3 ethyl esters (46% EPA, 38% DHA, and 4 mg of soy alpha-tocopherol) or a matching placebo daily for 12 weeks... The reduction in levels of inflammatory biomarkers and vascular stiffness associated with the intake of 2 grams of omega-3 daily in patients with higher cardiovascular risk due to hypertension and dyslipidemia suggests that this could be a highly accessible and scalable strategy to address the challenge of inflammaging in this population. While this is a surrogate outcome, it is linked to an increased risk of accelerated aging and events, particularly in an era of rising longevity and the need to reduce exposure to chronic systemic inflammation."

Biomarker • Clinical • Cardiovascular • Dyslipidemia • Hypertension • CRP

A Prospective, Multicenter, Randomized, Controlled, Open-Label, Blinded Endpoint Trial Evaluating the Efficacy, Safety, and Cost-Effectiveness of Omega-3 Ethyl Esters in Mixed Dyslipidemia (ChiCTR) - P=N/A | N=492 | Not yet recruiting | Sponsor: Beiing Anzhen Hospital. Capital Medical University; Beijing Association of Holistic Integrative Medicine

HEOR • New trial • Dyslipidemia • Metabolic Disorders • Mixed Hyperlipidemia

Comparative Risk of Atrial Fibrillation Onset in Statin-Treated Patients Initiating Icosapent Ethyl and Omega-3 Acid Ethyl Esters: A Retrospective Cohort Study. (PubMed, J Am Heart Assoc) - "These findings suggest that, in adult patients who are AF naïve, IPE may be associated with a higher risk of AF compared with DHA/EPA when used as add-on therapy with statins."

Journal • Retrospective data • Atrial Fibrillation • Cardiovascular • Dyslipidemia • Metabolic Disorders

Enhancing tofacitinib's therapeutic efficacy in murine arthritis with a synbiotic formulation comprising Bacillus megaterium DSM 32963 and an Omega-3 fatty acid lysine salt. (PubMed, Front Immunol) - "Our findings reveal that a combination of low-dose tofacitinib and the synbiotic (ldTofa+Syn) significantly improved all measured arthritis severity parameters, outperforming either single treatment as well as supplementation with a conventional omega-3 ethyl ester that showed no effects on disease severity. Additionally, there was a marked trend towards lower levels of the key inflammatory cytokines TNFα, IL-1β, and IL-6 in the ldTofa+Syn group. In conclusion, the specific synbiotic formulation shows promise as a complementary nutritional therapy for RA, improving disease outcomes and modulating immune responses."

Journal • Preclinical • Immunology • Inflammation • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • CRP • CXCL1 • IL1B • IL6 • TNFA